( February 3, 2025, 1:48 PM EST) -- ORLANDO, Fla. — In a pair of nearly identical orders, a Florida federal judge dismissed two complaints against compounding pharmacies filed by Novo Nordisk Inc., the manufacturer of three FDA-approved medicines for weight management and diabetes that contain semaglutide, finding that its claims are preempted by the Food, Drug and Cosmetic Act (FDCA)....